Engineering recombinase circuits for cellular diagnostic devices
Project Number1R01EB036085-01
Contact PI/Project LeaderWONG, WILSON
Awardee OrganizationBOSTON UNIVERSITY (CHARLES RIVER CAMPUS)
Description
Abstract Text
Genetically engineered mammalian cells have demonstrated enormous clinical potential, especially as cancer
therapy. Also, immune cells equipped with a single-input reporter circuit for tumor detection can achieve higher
sensitivity than traditional imaging and blood-based diagnostics in mice, thus highlighting their potential as diag-
nostic devices. While promising, a major challenge in cell-based therapeutics and diagnostics is sensitivity. As
such, installing signal amplification genetic circuits will greatly improve the sensitivity and performance of cell-
based devices. Furthermore, most therapeutics and diagnostics rely on detecting a single biomarker, drastically
limiting their specificity. Genetic circuits that can robustly and efficiently integrate multiple inputs, logically pro-
cess the information, and produce the desired outputs will be required to address this challenge.
One of the most important tools for genetic circuit engineering in mammalian cells is the site-specific recom-
binase. An advantage of a recombinase-based gene expression circuit is its ability to amplify weak input signals.
Furthermore, our lab and others have shown that recombinases are especially suitable for logic circuit engineer-
ing. We have also identified many split locations within several orthogonal recombinases, which were leveraged
to develop a large collection of small-molecule inducible recombinases with enhanced performance.
While we have a powerful collection of recombinase-based gene circuits, there are significant gaps in our toolkit
that severely limit their applicability. For instance, it remains challenging to connect recombinase to input sen-
sors that display minimal basal activity and sufficient dynamic range, which degrades the performance of recom-
binase-based circuits. Moreover, multi-input recombinase circuits typically require multiple orthogonal recom-
binases. Since recombinase can permanently modify DNA, it has a natural memory capability, which prevents
them from distinguishing sequential (e.g., A then B) vs. simultaneous appearance (A AND B) of inputs. Therefore,
it would be desirable to develop circuits that can integrate various inputs with as few recombinases as possible.
For this proposed work, we will develop digital enhancer circuits and self-assembled split recombinases for com-
binatorial logic sensing to amplify signals and improve specificity. We will demonstrate their applications in the
context of cellular diagnostic devices for ovarian cancer. To achieve our objectives, we will;
Aim 1: Design a recombinase-shRNA-based digital enhancer circuit to amplify input signals
Aim 2: Design a library of self-assembled split recombinases for combinatorial logic circuits
Our team has all the necessary expertise to accomplish this work, as demonstrated by our published work in
engineering recombinase circuits, in vivo tumor diagnostics, and tumor-targeting immune cells in vivo. Success
from this proposed work will lead to a transformative platform for engineering cellular diagnostic devices. Fur-
thermore, our work will also set the foundation for using engineered cells to detect other pathological conditions,
such as inflammation.
Public Health Relevance Statement
Public Health Statement
The genetic logic circuit is invaluable in basic research and has the potential to transform
diagnostics, cell fate reprogramming, tissue engineering, and cell therapy, but their sensitivity
and specificity need to be improved before they can be widely adopted. We proposed to
develop tools that can enhance the sensitivity and specificity of signal detection in immune cells.
Success from this work will greatly enhance our ability to design novel living devices for
therapeutic and diagnostic applications.
National Institute of Biomedical Imaging and Bioengineering
CFDA Code
286
DUNS Number
049435266
UEI
THL6A6JLE1S7
Project Start Date
01-August-2024
Project End Date
30-April-2028
Budget Start Date
01-August-2024
Budget End Date
30-April-2025
Project Funding Information for 2024
Total Funding
$478,544
Direct Costs
$290,026
Indirect Costs
$188,518
Year
Funding IC
FY Total Cost by IC
2024
National Institute of Biomedical Imaging and Bioengineering
$478,544
Year
Funding IC
FY Total Cost by IC
Sub Projects
No Sub Projects information available for 1R01EB036085-01
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 1R01EB036085-01
Patents
No Patents information available for 1R01EB036085-01
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 1R01EB036085-01
Clinical Studies
No Clinical Studies information available for 1R01EB036085-01
News and More
Related News Releases
No news release information available for 1R01EB036085-01
History
No Historical information available for 1R01EB036085-01
Similar Projects
No Similar Projects information available for 1R01EB036085-01